- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06643039
Nosokomial luftveisvirusinfeksjon (NOSOVIRUS)
Sykehuservervet luftveisvirusinfeksjon: en prospektiv multisenterstudie i Frankrike
Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing mask. However, vaccination remains the major preventive measure.
To date, data at French national level are insufficient to describe the epidemiology of these infections, including their burden, and the potential protection of patients if vaccination coverage of health care professionals/patients is satisfactory. In addition, better understanding of the clinical characteristics of HAVRI will make it possible to identify potential sources of transmission as soon as possible and to implement appropriate hygiene measures.
We will set up a hospital-based prospective multicenter study in Bordeaux, Paris-Bichat, Dijon and Lyon, involving four inclusion services (geriatrics, internal medicine and transplantation) per hospital.
The main objective of this study is to calculate the incidence rate of hospital-acquired infections for three respiratory viruses; influenza, SARS-CoV-2 and syncytial respiratory virus (SRV), referred to as HARVI, in participating services.
Volunteered health care professionals or hospitalized patients presenting with influenza-like illness (ILI) at admission or during their stay in the participating centers will be eligible to be enrolled during the two inclusion periods: (mid-October 2024 to mid-April 2025 and mid-October 2025 to mid-April 2026).
For each patient/health care professional, a nasopharyngeal swab will be collected. A questionnaire including demographic data, medical history, vaccination, and clinical and biological data of the viral episode will also be completed by the study team. Patients tested positive for one of the viruses studied will be considered "cases" and patients tested negative as "controls".
The collected data will be pseudonymized before statistical analyses. Statistical analyses will consist of calculating incidence rates, attack rates overall and by causative virus and analysis of factors associated with the occurrence of HARVI.
The prospective design of the study will optimize the quality of the collected data (ex. consolidate the documentation of both the clinical picture and vaccination in patients and health care professionals by reducing memory bias) and allow to calculate the incidence rates, the crude and adjusted relative risks of HARVI according to the studied factors, and to describe multiple outcomes (hospitalization in intensive care units, death, etc.) based on the causative virus.
The results of this research project will allow to:
- obtain epidemiological indicators associated with HARVI;
- estimate the impact of HARVI on the prognosis of patients in hospital;
- assess the impact of HARVI on the total length of hospital stay;
- identify risk factors associated with HARVI;
- use the results as an argument for vaccination in order to increase vaccination coverage of healthcare workers.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Philippe VANHEMS, MD, PhD
- Telefonnummer: +33 4 72 11 07 20
- E-post: Philippe.vanhems@chu-lyon.fr
Studer Kontakt Backup
- Navn: Mitra SAADATIAN-ELAHI
- Telefonnummer: +33 4 72 11 07 18
- E-post: Mitra.elahi@chu-lyon.fr
Studiesteder
-
-
-
Bordeaux, Frankrike, 33076
- Har ikke rekruttert ennå
- Pellegrin Hospital
-
Ta kontakt med:
- Anne Marie ROGUES, Professor
- Telefonnummer: +33 5 56 79 55 53
- E-post: anne-marie.rogues@chu-bordeaux.fr
-
Hovedetterforsker:
- Anne Marie ROGUES, Professor
-
Dijon, Frankrike, 21079
- Har ikke rekruttert ennå
- CHU Dijon
-
Ta kontakt med:
- Ludwig Serge AHO-GLELE, Professor
- Telefonnummer: +33 3 80 29 38 01
- E-post: ludwig.aho@chu-dijon.fr
-
Hovedetterforsker:
- Ludwig Serge AHO-GLELE, professor
-
Lyon, Frankrike, 69003
- Rekruttering
- Edouard Herriot Hospital
-
Ta kontakt med:
- Philippe VANHEMS, Professor
- Telefonnummer: +33 4 72 11 07 20
- E-post: Philippe.vanhems@chu-lyon.fr
-
Hovedetterforsker:
- Philippe VANHEMS, Professor
-
Paris, Frankrike
- Har ikke rekruttert ennå
- Saint Louis Hospital
-
Ta kontakt med:
- Nathalie DE CASTRO, Dr
- Telefonnummer: 01 42 49 48 20
- E-post: nathalie.de-castro@aphp.fr
-
Paris, Frankrike, 75877
- Har ikke rekruttert ennå
- Bichat Hospital
-
Ta kontakt med:
- Solen KERNEIS, Professor
- Telefonnummer: +33 1 40 25 60 59
- E-post: solen.kerneis@aphp.fr
-
Hovedetterforsker:
- Solen KERNEIS, professor
-
Paris, Frankrike, 75010
- Har ikke rekruttert ennå
- Saint Louis Hospital
-
Ta kontakt med:
- Guillaume MELLON, Dr
- Telefonnummer: 01 42 49 44 97
- E-post: guillaume.mellon@aphp.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults> 18 years old
- Hospitalized patient or health care professionals presenting an ILI on admission or during the stay, meeting the following definition: fever greater than 37.8° C in the absence of taking antipyretics and/or cough or pharyngeal pain.
- Signed consent form
Exclusion Criteria:
- Pregnant, parturient or breastfeeding women
- individuals deprived of their liberty by a judicial or administrative decision
- Individuals subject to psychiatric care
- Individuals admitted to a health or social establishment for purposes other than research
- Individuals under a legal protection measure (guardianship, curatorship)
- Individuals not affiliated to a social security insurance
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Patients hospitalized in participating services for more than 24h
Patients hospitalized for more than 24 hours in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) on admission or during hospital stay are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF. |
Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant. questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode. |
|
Annen: Volunteered health care professionals
Volunteered health care professionals in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF |
Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant. questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of hospital-acquired respiratory viral infections
Tidsramme: At inclusion
|
The primary endpoint will be evaluated by calculating the incidence of hospital-acquired respiratory viral infections overall and by type of virus (influenza, COVID-19, RSV) during the surveillance period. incidence rate will be estimated by the ration of number of incident cases over the study period to the cumulative observation time (in person-weeks) of hospitalized patients. Incidence density will be estimated by the ratio of number of incident cases during successive weekly observation periods to the cumulative observation times calculated over the same periods. |
At inclusion
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Sykdomsattributter
- Luftveisinfeksjoner
- Infeksjoner
- Orthomyxoviridae-infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Sykdommer i luftveiene
- Lungesykdommer
- Lungebetennelse, viral
- Lungebetennelse
- Coronavirus-infeksjoner
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- Iatrogen sykdom
- Patologiske tilstander, tegn og symptomer
- Covid-19
- Influensa, menneske
- Kryssinfeksjon
- Helsevesenets kvalitet, tilgang og evaluering
- Undersøkelsesteknikker
- Epidemiologiske metoder
- Datainnsamling
- Helsevesenets evalueringsmekanismer
- Kvalitet på helsehjelpen
- Folkehelse
- Miljø og folkehelse
- Undersøkelser og spørreskjemaer
Andre studie-ID-numre
- 69HCL23_1091
- 2024-A01267-40 (Annen identifikator: ID-RCB)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .